+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

New Targets for the Treatment of Hypertension and Associated Diseases. Advances in Pharmacology Volume 94

  • Book

  • June 2022
  • Elsevier Science and Technology
  • ID: 5527367

New Targets for the Treatment of Hypertension and Associated Diseases, Volume 94 in the Advances in Pharmacology serial, highlights new advances in the field, with this new volume presenting interesting chapters on Cytochrome P450, 20-hydroxyeicosatetraenoic acid and GPR75 pathway in hypertension, Treatment of hypertension with soluble epoxide hydrolase inhibitors, Effects of allosteric modifiers of adenosine receptors in the heart, Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury, Drugs affecting the nitric oxide- cyclic GMP pathway in hypertension, Relaxin-2 and Serelaxin in renal and cardiac dysfunction in hypertension, and more.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. The CYP/20-HETE/GPR75 axis in hypertension Ghezal Froogh, Victor Garcia and Michal L. Schwartzman 2. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury John D Imig 3. Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation Annika A. J�ttner, A.H. Jan Danser and Anton J.M. Roks 4. Sphingosine-1-phosphate and sphingosine-1-phosphate receptors in the cardiovascular system: Pharmacology and clinical implications Simona Federica Spampinato, Maria Angela Sortino and Salvatore Salomone 5. Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease Dominique Brown, Heather Alcala, Peter Oelschlaeger and Bradley T. Andresen 6. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension Prasad Chunduri, Shrey A. Patel and Scott P. Levick 7. Cardiovascular effects of GLP-1 receptor agonism Raymond J. Winquist and Valentin K. Gribkoff 8. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease HaiFeng Yang and Raouf A. Khalil 9. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Roberto Levi